Search
for
Sort by
Research 121–150 of 1000+
- Changing Patterns of Localization of Putative Stem Cells in Developing Human Hair Follicles
- Activin Controls Skin Morphogenesis and Wound Repair Predominantly via Stromal Cells and in a Concentration-Dependent Manner via Keratinocytes
- Epigen Transgenic Mice Develop Enlarged Sebaceous Glands
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia
- Cutaneous Drug Eruptions Associated with the Use of Biologies and Cutaneous Drug Eruptions Mimicking Specific Skin Diseases
- Accelerative action of topical piperonylic acid on mice full thickness wound by modulating inflammation and collagen deposition
- Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers
- The urine as a diagnostic key for a homozygous EGFR mutation
- Maintaining arc consistency using adaptive domain ordering
- A desmosomal cadherin controls multipotent hair follicle stem cell quiescence and orchestrates regeneration through adhesion signaling
- Specific In Vivo Ablation of Lrig1-Positive Follicular Progenitor Cells Results in Sebaceous Gland Loss in Mice
- Sesamin alleviates androgenetic alopecia by targeting the AR MAPK Wnt axis
- Pathogenesis and management of TRPV3-related Olmsted syndrome
- 870 Y27632 promotes proliferation via EGFR signaling in a newly isolated and characterized human primary sebocyte cell line
- 1312 Nrf2 activation enhances the healing of cutaneous wounds through the activation of hair follicle stem cells
- Cutaneous adverse effects of targeted therapies
- Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice.
- Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
- Spontaneous Squamous Cell Carcinoma Induced by the Somatic Inactivation of <i>Retinoblastoma</i> and <i>Trp53</i> Tumor Suppressors
- Drugs and Hair Loss
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Cutaneous side-effects of EGFR inhibitors and their management.
- Erosive Pustular Dermatosis of the Scalp-Like Eruption due to Gefitinib: Case Report and Review of the Literature of Alopecia Associated with EGFR Inhibitors
- Incidence and management of cutaneous toxicities associated with cetuximab
- A Case of Cicatricial Alopecia Associated with Erlotinib
- Trichoscopic Findings of Erosive Pustular Dermatosis of the Scalp Associated with Gefitinib
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- Skin toxicity caused by EGFR antagonists—An autoinflammatory condition triggered by deregulated IL‐1 signaling?
- Rash from EGFR inhibitors: Opportunities and challenges for palliation